SVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud Lawsuit

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud related to the FDA's refusal to file a Biologics License Application (BLA) for its product MOLBREEVI, which has led to a significant decline in share price [1][2][3]. Group 1: Lawsuit Details - The class action lawsuit is based on claims that Savara made false or misleading statements regarding the completeness of the MOLBREEVI BLA submission [3]. - The FDA's refusal to file letter indicated that the BLA was not sufficiently complete, particularly concerning Chemistry, Manufacturing, and Controls (CMC) [2][3]. - Following the announcement of the FDA's decision, Savara's share price dropped by $0.90, approximately 31.69%, from $2.84 to $1.94 [2]. Group 2: Investor Information - Investors who acquired Savara securities between March 7, 2024, and May 23, 2025, are urged to seek lead plaintiff appointment by the November 7, 2025 deadline [1]. - The law firm Kirby McInerney LLP is handling the case and encourages affected investors to contact them for more information [4][5].